Inventor

GLUCHOWSKI CHARLES

US71 patents

⚠️ This page may combine multiple inventors who share the name “GLUCHOWSKI CHARLES”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

GLUCHOWSKI CHARLES

SYNAPTIC PHARMA CORP

Benzimidazoles and benzothiazoles and uses thereof

Oxazolidinones and uses thereof

Aryl sulfonamides and sulfamide derivatives and uses thereof

Aryl sulfonamides and sulfamide derivatives and uses thereof

Substituted indoles and uses thereof

Oxazolidinones as α1A receptor antagonists

Substituted indoles and uses thereof

Substituted indoles and uses thereof

5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands

Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence

Use of α1C specific compounds to treat benign prostatic hyperlasia

Aromatic amine derivatives

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

Dihydropyridines and new uses thereof

Use of α-1C specific compounds to treat benign prostatic hyperplasia

Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof

Benzimidazole derivatives

Dihydropyrimidines and uses thereof

Dihydropyrimidines and uses thereof

Imidazole and imidazoline derivatives and uses thereof

Indole and benzothiazole derivatives

Benzimidazole derivatives

Imidazoline derivatives and uses thereof

Imidazole and imidazoline derivatives and uses thereof

Imidazole and imidazoline derivatives and uses thereof

5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines

Dihydropyridines and new uses thereof

Use of alpha-1C specific compounds to treat benign prostatic hyperplasia

ALLERGAN INC

Intraocular pressure reducing 9,11-diacyl prostaglandins

(2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same

6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents

(2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same

Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure

Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives

Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives

Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives

Method for producing amino-2-imidazoline derivatives

Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives

Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines

(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same

Method for producing amino-2-imidazoline derivatives

(2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same

Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenyl-amino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines

2-(hydroxy-2-alkylphenylamino)-oxazolines and thiazolines as anti-glaucoma and vasoconstrictive agents

Intraocular pressure reducing 15-acyl prostaglandins

Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines

Method for reducing or maintaining intraocular pressure

MANIV ENERGY CAPITAL

Methods of treating conditions associated with an Edg-3 receptor